REGN
REGENERON PHARMACEUTICALS, INC.
Overview
Regeneron Pharmaceuticals designs, develops, manufactures, and commercializes medicines for serious diseases including eye diseases, allergies, inflammation, cancer, cardiovascular disease, neurological conditions, and rare diseases.
REGENERON PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $64.50B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 29, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-2914 Q&A exchanges
- Q4 FY2025Earnings2026-01-3013 Q&A exchanges
- Q3 FY2025Earnings2025-10-2816 Q&A exchanges
- Q2 FY2025Earnings2025-08-0113 Q&A exchanges
- Q1 FY2025Earnings2025-04-2920 Q&A exchanges
- Q4 FY2024Earnings2025-02-0418 Q&A exchanges
- Q3 FY2024Earnings2024-10-3119 Q&A exchanges
- Q2 FY2024Earnings2024-08-0125 Q&A exchanges
- Q1 FY2024Earnings2024-05-0211 Q&A exchanges
- Q4 FY2023Earnings2024-02-029 Q&A exchanges
- Q3 FY2023Earnings2023-11-0218 Q&A exchanges
- Q2 FY2023Earnings2023-08-0322 Q&A exchanges
- Q1 FY2023Earnings2023-05-0414 Q&A exchanges
- Q4 FY2022Earnings2023-02-0313 Q&A exchanges
- Q3 FY2022Earnings2022-11-0316 Q&A exchanges
- Q2 FY2022Earnings2022-08-0315 Q&A exchanges
- Q1 FY2022Earnings2022-05-0414 Q&A exchanges
- Q4 FY2021Earnings2022-02-049 Q&A exchanges
- Q3 FY2021Earnings2021-11-0414 Q&A exchanges
- Q2 FY2021Earnings2021-08-0514 Q&A exchanges
- Q1 FY2021Earnings2021-05-0618 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-29EPS— vs $10.85—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-29 | — | $10.85 | — | — | — | — | EODHD |
Source: EODHD. REGN reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks REGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.87 | $2.74 | +41.4% | +2.3% | +0.4% |
| Q4 FY2026 | $3.73 | $2.55 | +46.1% | +5.5% | +2.7% |
| Q3 FY2026 | $3.79 | $2.60 | +45.7% | +5.3% | +6.6% |
| Q2 FY2026 | $3.50 | $2.66 | +31.4% | +0.7% | +1.4% |
| Q1 FY2025 | $3.86 | $2.70 | +42.9% | -6.0% | -8.0% |
| Q4 FY2025 | $4.02 | $2.88 | +39.7% | +4.9% | +5.4% |
| Q3 FY2025 | $3.81 | $2.68 | +42.0% | -3.9% | -3.2% |
| Q2 FY2025 | $3.64 | $2.78 | +30.9% | -1.3% | -3.7% |
| Q1 FY2024 | $4.37 | $2.99 | +46.3% | +3.5% | +1.4% |
| Q4 FY2024 | $3.58 | $2.72 | +31.5% | +3.6% | +3.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Leonard S SchleiferCEO6 mo20 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Christopher R FenimoreCFO6 mo9 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- George YancopoulosPresident6 mo20 callsCurrentSample
PRESIDENT since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Jason PitofskySVP Controller4 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2026
- Plew Daniel P VanEVP & General Mgr, Industrial6 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
- Marion McCourtEVP Commercial6 mo21 callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for REGN.
$ curl https://api.spokenalpha.com/v1/companies/REGNFAQ
Frequently asked about REGN
Where can I find REGENERON PHARMACEUTICALS, INC.'s (REGN) earnings call transcripts?
Spoken Alpha indexes REGN's earnings call transcripts at https://spokenalpha.com/companies/REGN. Each call links to attributed speakers and parsed analyst Q&A. REGENERON PHARMACEUTICALS, INC.'s own investor relations page is at https://investor.regeneron.com/.
When was REGENERON PHARMACEUTICALS, INC.'s most recent earnings call?
REGENERON PHARMACEUTICALS, INC. (REGN) held its most recent earnings call on 2026-04-29, covering fiscal Q1 2026.
What sector is REGN in?
REGENERON PHARMACEUTICALS, INC. (REGN) operates in the Healthcare sector (Biotechnology industry).